Organic compounds -- part of the class 532-570 series – Organic compounds – Unsubstituted hydrocarbyl chain between the ring and the -c-...
Patent
1993-05-07
1996-09-17
Shah, Mukund J.
Organic compounds -- part of the class 532-570 series
Organic compounds
Unsubstituted hydrocarbyl chain between the ring and the -c-...
540450, 540474, 424 93, 534 15, C07D24502, C07D25900, A61K 4900
Patent
active
055569684
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to certain novel macrocyclic chelating agents, in particular derivatised polyamines, and to their uses, especially their medical uses.
BACKGROUND OF THE INVENTION
The medical use of chelating agents is well established, for example as stabilizers for pharmaceutical preparations, as antidotes for poisonous heavy metal species and as diagnostic agents for the administration of metal species (e.g. ions or atoms) for diagnostic techniques such as X-ray, magnetic resonance imaging (MRI) or ultrasound imaging or scintigraphy.
Polyamine chelating agents, for example aminopoly(carboxylic acid or carboxylic acid derivative) (hereinafter APCA) chelating agents and their metal chelates, are well known and are described for example in U.S. Pat. No. 2,407,645 (Bersworth), U.S. Pat. No. 2,387,735 (Bersworth), EP-A-71564 (Schering), EP-A-130934 (Schering), EP-A-165728 (Nycomed AS), DE-A-2918842 (Rexolin Chemicals AB), DE-A-3401052 (Schering), EP-A-258616 (Salutar), DE-A-3633245 (Schering) EP-A-263059 (Schering), EP-A-277088 (Schering) and DE-A-3633243 (IDF).
Thus, for example, EP-A-71564 describes paramagnetic metal chelates, for which the chelating agents are nitrilotriacetic acid (NTA), N,N,N',N'-ethylenediaminetetraacetic acid (EDTA), N-hydroxyethyl-N,N',N'-ethylenediaminetriacetic acid (HEDTA), N,N,N',N",N"-diethylenetriaminepentaacetic acid (DTPA) and N-hydroxyethyliminodiacetic acid, as being suitable as contrast agents for MRI, contrast being achieved by the effect on surrounding solvent protons of the magnetic field of the paramagnetic species (e.g. Gd(III)), with the chelating agents serving to reduce the toxicity and to assist administration of that paramagnetic species. Amongst the particular metal chelates disclosed by EP-A-71564 was GdDTPA, the use of which as an MRI contrast agent has recently received much attention. The Gd(III) chelate of 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA), referred to in DE-A-3401052 (Schering) and in U.S. Pat. No. 4,639,365 (University of Texas), has also recently received attention in this regard.
To improve stability, water solubility and selectivity, relative to the APCA chelating agents described in EP-A-71564, Schering, in EP-A-130934, have proposed the partial substitution for the N-attached carboxyalkyl groups of alkyl, alkoxyalkyl, alkoxycarbonylalkyl or alkylaminocarbonylalkyl groups, where any amide nitrogens may themselves carry polyhydroxyalkyl groups. More recently, to improve compatibility, stability, solubility and selectivity, in EP-A-250358 Schering have proposed a narrow range of compounds having a DTPA-like structure including a bridging alkylene chain.
In the field of hepatobiliary MRI contrast agents, where lipophilicity rather than hydrophilicity is desired, Nycomed in EP-A-165728, have proposed the use of paramagnetic chelates of certain anilide group-containing iminodiacetic acids and Lauffer in WO-A-86/06605 has suggested the use of paramagnetic chelates of triaza and tetraaza macrocycles which carry a fused aromatic ring but are otherwise unsubstituted.
Nycomed, in EP-A-299795, suggest that the toxicity of certain APCA chelating agents and their chelates may be reduced by introducing at least one hydrophillic moiety as a substituent on one or more of the alkylene bridges between the amine nitrogens.
However, all hitherto known APCA chelating agents and their metal chelates encounter problems of toxicity, stability or selectivity and there is thus a general and continuing need for such polyamine chelating agents which form metal chelates of reduced toxicity, improved stability or improved water solubility. In particular there is perceived to be a need for chelants which form highly stable metal chelates which can be used to produce low osmolality contrast media.
SUMMARY OF THE INVENTION
We now propose a novel class of macrocyclic polyamine chelating agents which incorporate at least two peptide linkages within the macrocyclic skeleton.
Thus viewed from one aspect the present invention
REFERENCES:
patent: 3723087 (1973-03-01), Chapp
patent: 4999349 (1991-03-01), Toda et al.
patent: 5025023 (1989-09-01), Konishi et al.
patent: 5132409 (1992-07-01), Felder et al.
patent: 5194605 (1993-03-01), Greenlee et al.
Carvalho Joan F.
Crofts Shaun P.
Varadarajan John
Nycomed Salutar Inc.
Shah Mukund J.
Sripada P. K.
LandOfFree
Polyazamacrocycle chelating agents with amide linkages does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyazamacrocycle chelating agents with amide linkages, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyazamacrocycle chelating agents with amide linkages will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-414079